Time period What may be noticeable What the evidence supports Weeks 1-4 Satiety, appetite changes, nausea, bowel changes, early scale movement Early tolerability period, not the main efficacy endpoint window Weeks 4-12 More consistent appetite suppression and early weight trend Direction of response may become clearer, but individual variance is high Weeks 12-24 Clinically meaningful separation becomes easier to evaluate Phase 2 primary endpoint at 24 weeks showed dose-dependent weight loss Weeks 24-48 Major body-weight reduction window in Phase 2 48-week Phase 2 secondary endpoint showed the largest published Phase 2 changes Weeks 68-104 Longer-term Phase 3 and extension outcomes TRIUMPH program endpoints measure durability over longer windows Weeks 1-4: Early Signals, Not Final Results The first few weeks are usually the wrong window for judging full retatrutide results
The structure was determined by molecular replacement and refined to a resolution of 2.0 (Table 1)
A automedicao deve ser evitada
Think of it like blood pressure medicationit works while youre taking it, but the underlying condition requires ongoing management
NAION is the most common cause of sudden blindness due to damage of the optic nerve, and is second only to glaucoma as an overall cause of optic nerve blindness, researchers said
Perin et al
